Aurora Cannabis (ACB) Income from Non-Controlling Interests (2018 - 2026)
Aurora Cannabis (ACB) posted quarterly Income from Non-Controlling Interests of $7.3 million for Q1 2026, up 435.49% year-over-year from $1.4 million in Q1 2025, and up 371.88% quarter-over-quarter from -$2.7 million in Q4 2025.
Aurora Cannabis (ACB) Income from Non-Controlling Interests (2018 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Income from Non-Controlling Interests for 8 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 435.49% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $84057.7 (up 115.06% YoY), while the FY2025 annual figure was -$487005.4, up 82.47% from the prior year.
- Income from Non-Controlling Interests climbed to $7.3 million in Q1 2026 per ACB's latest filing, from -$2.7 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $7.3 million in Q1 2026 and bottomed at -$3.4 million in Q2 2025.
- Historically, Income from Non-Controlling Interests has averaged -$260404.2 across 5 years, with a median of -$677341.4 in 2024.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests slumped 1044.0% — and 2026, when it jumped 435.49%.
- Aurora Cannabis' Income from Non-Controlling Interests stood at -$1.5 million in 2022, then jumped by 48.58% to -$781545.8 in 2023, then surged by 70.14% to -$233366.8 in 2024, then plunged by 1044.0% to -$2.7 million in 2025, then surged by 371.88% to $7.3 million in 2026.
- Business Quant data shows ACB's Income from Non-Controlling Interests at $7.3 million in Q1 2026, -$2.7 million in Q4 2025, and -$1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aurora Cannabis | 235.30 Mn | 162.99 Mn | 25.75 Mn | 500,987.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.26 Mn |
| Dec 31, 2025 | -2.67 Mn |
| Sep 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | -233,366.82 |
| Sep 30, 2024 | -677,341.35 |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | 264,934.42 |
| Dec 31, 2023 | -781,545.80 |
| Sep 30, 2023 | -1.20 Mn |
| Dec 31, 2022 | -1.52 Mn |
| Sep 30, 2022 | -216,989.19 |
| Jun 30, 2022 | 8,627.75 |
| Mar 31, 2022 | 9,473.70 |
| Dec 31, 2021 | -291,154.34 |
| Sep 30, 2020 | -1.10 Mn |
| Sep 30, 2018 | -979,927.44 |